Cancer Research Institute and IQVIA Uncover the Impact of COVID-19 Pandemic on Global Oncology Clinical Trials
May 19, 2020
May 19, 2020
NEW YORK, May 19 -- Cancer Research Institute issued the following news:
The Cancer Research Institute (CRI) and IQVIA(TM) (NYSE:IQV) have published new findings in Nature Reviews Drug Discovery on the current challenges, risks, and contingencies for global oncology trial management amid the COVID-19 pandemic. The study adds to the growing analysis of COVID-19's impact on R&D activities, and the downstream effect on new or improved treatments.
Between March 17 and A . . .
The Cancer Research Institute (CRI) and IQVIA(TM) (NYSE:IQV) have published new findings in Nature Reviews Drug Discovery on the current challenges, risks, and contingencies for global oncology trial management amid the COVID-19 pandemic. The study adds to the growing analysis of COVID-19's impact on R&D activities, and the downstream effect on new or improved treatments.
Between March 17 and A . . .